Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CVTX - CV Therapeutics, Inc. -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (152)	12/9/2003 9:19:06 PM
From: mopgcw	Read Replies (1) \| Respond to of 411

My issue is that there is mostly nothing new here, this should have been priced into the stock already...obviously I was mistaken. This is why agreed with MZ when the stock was in the mid $20's, but was a buyer as it tanked to the mid teens on the approvable letter news. Everyone knew more study would be required pushing it out Given the lack of focus on QTc, I think the outcome is a bit better than expected -- the rat toxicity issue is a new one though. Net net, it seems more compelling to me here at $12, and if it does swoon to single digits, I will double down yet again. Figure they burn another $20mm leaving $440mm in cash, $14/share tangible book value. The debt is not due until 2007 ($196) and 2010 ($100). They figure they have cash enough to cover 24 months of burn. Net all of the debt and you get $4.70 cash/share -- but that is not realistic. interesting to watch unfold.